Radiation and pembrolizumab before surgery for oral cavity cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether giving a type of radiation therapy (proton or photon) along with the immunotherapy drug pembrolizumab before surgery is safe and effective for people with certain oral cavity cancers. The goal is to see if this combination can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of HPV-negative squamous cell carcinoma of the oral cavity.
- Your cancer must be either locally advanced (stage T3-T4) or recurrent in the same area, but you must not have had radiation to the head or neck before.
- You must be able to undergo radiation and immunotherapy (pembrolizumab) before surgery.
- You must have a PD-L1 combined positive score of 1 or higher.
- You must be willing to provide tissue and blood samples for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, XL-092 and pembrolizumab (Keytruda), given before surgery for a type of mouth cancer that is HPV-negative and can be removed. The goal is to see if this treatment helps shrink the tumor and improves outcomes.
This Phase 2 trial tests pembrolizumab (an immune therapy) given before surgery to see if it can help control high-risk invasive cutaneous squamous cell carcinoma. The goal is to improve outcomes by treating cancer earlier and then following with standard surgery and radiation if needed.
This study tests if giving immunotherapy before surgery helps treat oral cavity cancer. Researchers will look for markers in your biopsy that predict how well the treatment works.
This trial tests combining radiation therapy with immunotherapy and chemotherapy before surgery for advanced oral or throat cancer. The goal is to see if this approach can shrink the tumor and improve treatment outcomes.
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
Hear when a new Locally Recurrent Oral Cavity Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.